ImmunityBio Inc.

ImmunityBio Inc.

World Rank (Aug-2026)
2596
Market Cap (Aug-2026)
8.023 Billion USD
World Rank (Jan-05-2024)
4,154
Market Cap (Jan-05-2024)
3.225 Billion USD
World Rank (Jul-30-2023)
8,650
Market Cap (Jul-30-2023)
1.016 Billion USD
World Rank (Jan-07-2022)
5,471
Market Cap (Jan-07-2022)
2.502 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
IBRX
Employee Count
587
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
113 Million USD
Annual Operating Income in USD
-256 Million USD
Annual Net Income in USD
-351 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
502 Million USD
Total Liabilities in USD
1,001 Million USD
Total Equity in USD
-500 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Company Website
IMMUNITYBIO, INC.
Company Profile
ImmunityBio is a Late Clinical Stage Immunotherapy company for treating cancer and infectious diseases. The headquarters is in USA.
Founded Year
2014
IPO Year
2015
Stock Exchange
Frankfurt
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share